Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia

The authors investigate the differential effects of ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) on fracture risk and bone metabolism in patients with iron deficiency anemia. Their findings reveal that FCM is associated with a significantly higher incidence of osteomalacia and fractures compared to FDI, which they attribute to FCM's impact on bone formation and mineral metabolism, as demonstrated in both patient cohorts and mouse models. The study highlights the potential mechanisms by which FCM treatment may impair bone health, suggesting a need for caution in its use.